We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

71 hedge funds and large institutions have $159M invested in Spyre Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

29% more capital invested

Capital invested by funds: $123M → $159M (+$36.1M)

18% more funds holding

Funds holding: 60 → 71 (+11)

0% more ownership

Funds ownership: 2.74% → 2.74% (+0%)

Holders
71
Holders Change
+11
Holders Change %
+18.33%
% of All Funds
1.54%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
17
Increased
25
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$4.17M
2
Goldman Sachs
Goldman Sachs
New York
+$3.22M
3
Marshall Wace
Marshall Wace
United Kingdom
+$3.13M
4
SFM
Sphera Funds Management
Israel
+$3.13M
5
ACM
Aisling Capital Management
New York
+$2.94M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$4.8M
2
Man Group
Man Group
United Kingdom
-$286K
3
Squarepoint
Squarepoint
New York
-$173K
4
Morgan Stanley
Morgan Stanley
New York
-$152K
5
TI
Trexquant Investment
Connecticut
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$21.4M +$1.04M +5,000 +5%
O
2
OrbiMed
New York
$17.4M – – –
BBA
3
Baker Bros. Advisors
New York
$13.8M – – –
BlackRock
4
BlackRock
New York
$12M +$1.55M +7,454 +14%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$11.8M +$83.4K +400 +0.7%
ACM
6
Aisling Capital Management
New York
$9.83M +$2.94M +14,091 +41%
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.94M +$2.75M +13,200 +42%
SFM
8
Sphera Funds Management
Israel
$7.85M +$3.13M +15,000 +63%
RSCM
9
Rock Springs Capital Management
Maryland
$6.44M +$1.25M +6,000 +23%
Jennison Associates
10
Jennison Associates
New York
$6.25M -$4.8M -23,028 -43%
DM
11
Deerfield Management
New York
$4.03M +$4.17M +20,002 New
Renaissance Technologies
12
Renaissance Technologies
New York
$3.65M -$22.5K -108 -0.6%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$3.63M +$1.37M +6,575 +57%
Goldman Sachs
14
Goldman Sachs
New York
$3.25M +$3.22M +15,430 +2,182%
Marshall Wace
15
Marshall Wace
United Kingdom
$3.03M +$3.13M +15,036 New
UOTTAIMCU
16
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$2.7M – – –
RWM
17
Ritholtz Wealth Management
New York
$2.34M – – –
CH
18
CVI Holdings
Delaware
$2.19M +$2.26M +10,862 New
State Street
19
State Street
Massachusetts
$1.97M -$8.55K -41 -0.4%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$1.94M +$651K +3,125 +48%
A
21
Abingworth
United Kingdom
$1.93M +$2.01M +9,620 New
Northern Trust
22
Northern Trust
Illinois
$1.74M +$277K +1,328 +18%
FI
23
Fosun International
China
$1.4M +$659K +3,160 +81%
Citadel Advisors
24
Citadel Advisors
Florida
$960K +$994K +4,768 New
BCM
25
Bridgeway Capital Management
Texas
$825K – – –
1
2 3 4

SYRE Hedge Fund Activity: Q1 2019 in Review

71 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2019, worth a combined $159M — up 29% from $123M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new SYRE positions and 6 closed out — a net gain of 11 holders — while 25 added to existing stakes and 12 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $4.17M. The largest seller was Jennison Associates, cutting an estimated $4.8M.

  • 71 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2019, up from 60 in Q4 2018.
  • Funds reported $159M of Spyre Therapeutics stock for Q1 2019, up 29% quarter-over-quarter.
  • 17 funds opened new Spyre Therapeutics positions in Q1 2019 and 6 closed out, a net change of +11 holders.
  • The largest Spyre Therapeutics buyer in Q1 2019 was Deerfield Management, an estimated $4.17M added.
  • The largest Spyre Therapeutics seller in Q1 2019 was Jennison Associates, an estimated $4.8M sold.

Based on aggregated 13F filings for Q1 2019.